{"id":808574,"date":"2025-02-04T09:28:02","date_gmt":"2025-02-04T14:28:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\/"},"modified":"2025-02-04T09:28:02","modified_gmt":"2025-02-04T14:28:02","slug":"jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\/","title":{"rendered":"Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones"},"content":{"rendered":"
\n

Jupiter, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) — Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (\u201cJupiter\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing JOTROL\u2122<\/sup>, a patented resveratrol-based platform, today issued a statement regarding recent market volatility and highlighted its planned Direct-to-Consumer product launch later this year, which is expected to generate near-term revenues while the Company advances its clinical trials.<\/p>\n

\u201cThe recent volatility in our stock appears to be driven by misconceptions and a lack of understanding about our business and long-term strategy, but I want to reassure our investors that there have been no undisclosed material developments,\u201d said Christer Ros\u00e9n, Chairman and CEO of Jupiter Neurosciences. \u201cOur recent announcements, including partnerships with Zina Biopharmaceuticals and Catalent Pharma Solutions, are important milestones in advancing JOTROL\u2122 for our planned Phase 2a study in Parkinson\u2019s disease. With these partnerships in place, we are making tangible progress in our clinical development and remain confident in the path ahead.\u201d<\/p>\n

Jupiter is advancing a robust clinical pipeline addressing combined market opportunities exceeding $50 billion. The Company is focused on significant unmet needs in CNS disorders, including Alzheimer\u2019s, Parkinson\u2019s, and rare diseases such as MPS-I, Friedreich\u2019s Ataxia, and MELAS. With multiple Phase 2 trials scheduled to launch within the next 12 months\u2014leveraging successful Phase 1 data demonstrating safety\u2014Jupiter is well-positioned for meaningful clinical advancements.<\/p>\n

In addition to its clinical pipeline development, Jupiter is poised to generate near-term revenue with the upcoming launch of its direct-to-consumer product line in 2025. This initiative represents a key step in diversifying the Company\u2019s business model, providing immediate cash flow while continuing to advance its pharmaceutical pipeline. Focused on the longevity and aging market, the Company expects to share more details soon about two initial products leveraging the unique bioavailability and therapeutic advantages of JOTROL\u2122, which has demonstrated significantly enhanced bioavailability compared to traditional resveratrol formulations.<\/p>\n

Ros\u00e9n also commented on the Company\u2019s financial strategy: \u201cWhile we remain open to strategic funding opportunities, we are committed to avoiding toxic debt and ensuring that we maintain a sustainable approach to financing our operations. With $1.76 million in NIH funding secured and an additional $16 million in grants under review, alongside the $11 million raised in our December 2024 IPO, we are well-positioned to advance our clinical and commercial initiatives. Furthermore, our strategic collaborations with Harvard University, Georgetown University, MIT\u2019s Picower Institute for Learning & Memory, and the University of Miami Miller School of Medicine enhance our research and clinical capabilities, while our efforts to build licensing and commercialization partnerships in Asia position us for future global expansion.\u201d<\/p>\n

\u201cDespite market fluctuations, our commitment to executing on our strategy remains unchanged,\u201d said Ros\u00e9n. \u201cWe believe in the potential of JOTROL\u2122 and our broader pipeline to address neuroinflammatory diseases and aging-related health solutions. Our team remains focused on driving progress, creating value for our investors, and ultimately delivering transformative treatments for patients.\u201d<\/p>\n

As always, Jupiter encourages investors to review its filings with the SEC and corporate announcements for the latest company updates.<\/p>\n

\n About Jupiter Neurosciences, Inc.<\/strong>\n <\/p>\n

Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company\u2019s platform product, JOTROL\u2122<\/sup>, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company\u2019s pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer\u2019s Disease, Parkinson\u2019s Disease, Mucopolysaccharidoses Type I, Friedreich\u2019s Ataxia, and MELAS. More information may be found on the Company\u2019s website\u00a0www.jupiterneurosciences.com<\/a>.<\/u><\/p>\n

\n About JOTROL <\/strong>\n <\/p>\n

Resveratrol is one of the world\u2019s most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng\/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.<\/p>\n

Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI\/Early Alzheimer\u2019s Disease trial, and Yui et al., Friedreich\u2019s Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL trials, were published in the Journal of Alzheimer\u2019s Disease<\/em> and AAPS Open<\/em> in February 2022.<\/p>\n

\n About Zina Biopharmaceuticals, LLC<\/strong>\n <\/p>\n

Zina Biopharmaceuticals, co-founded by Professor Charbel Moussa, is a specialized consulting company providing end-to-end trial design and execution solutions as well as regulatory, scientific and medical advice for biotech and pharmaceutical companies.<\/p>\n

\n FORWARD-LOOKING STATEMENTS<\/strong>\n <\/p>\n

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company\u2019s current expectations, including the use of proceeds from the Offering. Investors can find many (but not all) of these statements by the use of words such as \u201capproximates,\u201d \u201cbelieves,\u201d \u201chopes,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cestimates,\u201d \u201cprojects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cmay\u201d or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company\u2019s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company\u2019s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.<\/p>\n

\n Contact: <\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
1-800-RED-CHIP (733-2447)
JUNS@redchip.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Jupiter, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) — Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (\u201cJupiter\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing JOTROL\u2122, a patented resveratrol-based platform, today issued a statement regarding recent market volatility and highlighted its planned Direct-to-Consumer product launch later this year, which is expected to generate near-term revenues while the Company advances its clinical trials. \u201cThe recent volatility in our stock appears to be driven by misconceptions and a lack of understanding about our business and long-term strategy, but I want to reassure our investors that there have been no undisclosed material developments,\u201d said Christer Ros\u00e9n, Chairman and CEO of Jupiter Neurosciences. \u201cOur recent announcements, including partnerships with Zina Biopharmaceuticals and Catalent Pharma Solutions, are important … <\/p>\n

Continue reading “Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-808574","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nJupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Jupiter, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) — Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (\u201cJupiter\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing JOTROL\u2122, a patented resveratrol-based platform, today issued a statement regarding recent market volatility and highlighted its planned Direct-to-Consumer product launch later this year, which is expected to generate near-term revenues while the Company advances its clinical trials. \u201cThe recent volatility in our stock appears to be driven by misconceptions and a lack of understanding about our business and long-term strategy, but I want to reassure our investors that there have been no undisclosed material developments,\u201d said Christer Ros\u00e9n, Chairman and CEO of Jupiter Neurosciences. \u201cOur recent announcements, including partnerships with Zina Biopharmaceuticals and Catalent Pharma Solutions, are important … Continue reading "Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-04T14:28:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MjczOSM2NzM0OTE4IzUwMDEzMDYzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones\",\"datePublished\":\"2025-02-04T14:28:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\\\/\"},\"wordCount\":982,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1MjczOSM2NzM0OTE4IzUwMDEzMDYzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\\\/\",\"name\":\"Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1MjczOSM2NzM0OTE4IzUwMDEzMDYzOQ==\",\"datePublished\":\"2025-02-04T14:28:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1MjczOSM2NzM0OTE4IzUwMDEzMDYzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1MjczOSM2NzM0OTE4IzUwMDEzMDYzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\/","og_locale":"en_US","og_type":"article","og_title":"Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - Market Newsdesk","og_description":"Jupiter, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) — Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (\u201cJupiter\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing JOTROL\u2122, a patented resveratrol-based platform, today issued a statement regarding recent market volatility and highlighted its planned Direct-to-Consumer product launch later this year, which is expected to generate near-term revenues while the Company advances its clinical trials. \u201cThe recent volatility in our stock appears to be driven by misconceptions and a lack of understanding about our business and long-term strategy, but I want to reassure our investors that there have been no undisclosed material developments,\u201d said Christer Ros\u00e9n, Chairman and CEO of Jupiter Neurosciences. \u201cOur recent announcements, including partnerships with Zina Biopharmaceuticals and Catalent Pharma Solutions, are important … Continue reading \"Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-04T14:28:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MjczOSM2NzM0OTE4IzUwMDEzMDYzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones","datePublished":"2025-02-04T14:28:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\/"},"wordCount":982,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MjczOSM2NzM0OTE4IzUwMDEzMDYzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\/","name":"Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MjczOSM2NzM0OTE4IzUwMDEzMDYzOQ==","datePublished":"2025-02-04T14:28:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MjczOSM2NzM0OTE4IzUwMDEzMDYzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MjczOSM2NzM0OTE4IzUwMDEzMDYzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-addresses-market-volatility-as-it-remains-focused-on-advancing-clinical-and-commercial-milestones\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/808574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=808574"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/808574\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=808574"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=808574"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=808574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}